(3-dimyristyloxypropyl)(dimethyl)(hydroxyethyl)ammonium has been researched along with Urinary Bladder Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fair, WR; Gilboa, E; Heston, WD; Horiguchi, Y; Larchian, WA; Nair, SK | 1 |
1 other study(ies) available for (3-dimyristyloxypropyl)(dimethyl)(hydroxyethyl)ammonium and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Topics: Animals; B7-1 Antigen; Cancer Vaccines; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Carriers; Female; Genetic Therapy; Glycerophospholipids; Interleukin-2; Lipids; Liposomes; Mice; Mice, Inbred C3H; Phosphatidylethanolamines; Quaternary Ammonium Compounds; Recombinant Proteins; T-Lymphocytes, Cytotoxic; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |